Combined Therapy Targeted Leukaemia Cells
Researchers found that pairing BCR inhibitors with anti-CXCR4 antibodies improved cancer cell destruction.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Do you believe developing new combination cancer therapies is the best way to improve patient survival?
Scientists discovered that BCR inhibitors increase CXCR4 receptor levels on chronic lymphocytic leukaemia cells, inadvertently creating a new target for treatment. Combining these inhibitors with ulocuplumab antibodies significantly reduced leukaemia cell survival in laboratory and mouse models.
Why it matters
This study identifies a mechanism where cancer cells adapt to BCR inhibitor treatment, providing a pathway to overcome drug resistance. By exploiting the increased presence of CXCR4 receptors, researchers can develop more effective combination therapies for patients.
In laboratory tests and mouse models, combination therapy reduced leukaemia cell survival to approximately 30-40% of the population, compared to a 70% survival rate when using BCR inhibitors alone.
The players
CEITEC Masaryk University
This is a research center based in Brno that focuses on life sciences and advanced materials.
Dana-Farber Cancer Institute
This Boston-based institute is a leading cancer treatment and research facility associated with Harvard Medical School.
University Hospital Brno
This facility is a major medical and research institution located in the Czech Republic.
The details
The research team analyzed patient samples collected before and during BCR inhibitor treatment to document the rise in CXCR4 receptor abundance on cell surfaces. By introducing the antibody ulocuplumab to the treatment regimen, the scientists successfully targeted these receptors to kill significantly more leukaemia cells than conventional methods.
Timeline
The study findings were published in HemaSphere on October 8, 2026.
The Big Picture
This discovery extends the current understanding of the ongoing research into BCR inhibitor resistance mechanisms by highlighting a specific receptor-driven target.
These findings suggest that future treatment protocols for chronic lymphocytic leukaemia may eventually include combination therapies that target specific cell receptors. Patients currently undergoing treatment should discuss their specific drug regimens and potential emerging trials with their oncology specialists.
The takeaway
This research demonstrates how understanding the adaptive behavior of cancer cells can lead to smarter, more precise treatment strategies. Patients and providers can watch for future clinical trials that test these combination therapies in human cohorts.
Further reading
Learn more about the latest research and breakthroughs in the Cancer section.
Source note: This article includes information reported by Central European Institute of Technology.
Live Poll
Do you believe developing new combination cancer therapies is the best way to improve patient survival?
